ClinicalTrials.gg
Not yet recruitingNCT06241391Updated Feb 8, 2024

Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas

An interventional study of PSMA PET-CT in Glioma, Astrocytoma and Anaplastic Astrocytoma, sponsored by All India Institute of Medical Sciences, Bhubaneswar. Not yet recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by All India Institute of Medical Sciences, Bhubaneswar · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Glioma with a site in India — 8 open to participants now, 8 under way, none of them phase 3. Glioma · India.

Started
2024
with 1 other
No phase
4 of 19
3 open now
Registered
10th of 19
by date
Lead sponsor
1 of 19
All India Institute of Medical Sciences, Bhubaneswar

Among the 19 studies in Glioma with a site in India, this one is one of 2 that started in 2024, is one of 4 with no phase, and was the 10th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

8 of the 19 studies in Glioma with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Glioma with a site in India, or all of them as a file.
02

Study summary

As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids analogues. Among these, 18F-FDG is the most commonly used tracer due to its broader use and easy availability. However, high physiological uptake in the brain is a significant limitation. The main limitation of other tracers is the need for onsite cyclotrons for their production, making their availability difficult. So, the search for an ideal modality is still ongoing, and the latest addition to this search is a radio ligand labeled Prostate Specific Membrane Antigen (PSMA). It is a new but potentially promising radiotracer, currently showing its utility in different malignancies. Investigators, therefore, aim to identify whether Ga-68 PSMA PET-CT has better diagnostic accuracy in the detection of recurrent gliomas than conventional imaging modalities.

Read the detailed description

Prostate Specific Membrane Antigen (PSMA is a type II membrane glycoprotein and is typically overexpressed in primary and metastatic lesions of prostate malignancy as the name suggests. However, this overexpression is not limited to prostate cancer only. It has been reported that, PSMA is overtly expressed in the vascular endothelium of various other malignancies where significant neovascularization is seen. Gliomas being highly vascularized tumors, have shown significant PSMA expression in their vascular endothelium especially in high grade ones. If this PSMA expression can be assessed through noninvasive molecular imaging, this would further ease the management these tumors. Different lesions have shown different grades of PSMA uptake in the PET/CT with high grade gliomas showing high uptake. Most of the articles published till date are either case reports or studies comprising very few numbers of patients. We would like to use the PET tracer Ga -68 PSMA for the detection of recurrence in patients with glioma.

Investigators believe that 68 Ga PSMA PET-CT has the potential to play an imperative role in noninvasively evaluating recurrent gliomas and can overcome the limitations of the currently used modalities. Besides, extrapolation of the PSMA expression, which is indirect evidence of neovascularization, can also be used to assess treatment options like VEGF inhibitors (Bevacizumab). These studies can also pave the way for further studies involving PSMA-based radio ligand therapy, which is currently being successfully applied in patients with metastatic prostate cancer.

03

Conditions studied

  • Glioma
  • Astrocytoma
  • Anaplastic Astrocytoma
  • Oligodendroglioma
  • Glioblastoma Multiforme

Keywords

  • FDG PET-CT
  • PSMA PET-CT
  • MRI brain
  • Glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with age more than18 years.
  • Patients having past history of proven glioma.
  • Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy.
  • Clinically suspected cases of recurrence.
  • Patient should be willing to and able to give written

Exclusion criteria

Exclusion Criteria:

  • Pregnant lady.
  • Breastfeeding mother.
  • Patients who will deny to give consent.
  • Any brain primary other than high grade glioma
  • Patient diagnosed with other primary
  • Patient with life threating neurological emergency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Efficiency of 68 Ga-PSMA-11 PET-CT in detection of recurrent gliomas

    Primary objective Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas Secondary objectives 1. Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images 2. Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas 3. Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan 4. Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan. 5. Any adverse events of Ga-68 PSMA-11 will be recorded according to CTCAE

    Diagnostic Test: PSMA PET-CT

Interventions

  • Diagnostic testPSMA PET-CT

    Prostate Specific Membrane Antigen PET-CT

06

What researchers measure

Primary outcomes

  1. Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas

    Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas

    Time frame: 3 months

Secondary outcomes

  1. Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images

    Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images

    Time frame: 3 months

  2. Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas

    Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas

    Time frame: 3 months

  3. Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan

    Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan

    Time frame: 3 months

  4. Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.

    Correlation between PSMA expression in histopathology specimen (using IHC) and

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — IPD data will be shared after obtaining permission from the institute post completion of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Dec 2024, 10 months later.

Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 10 months is below that.

Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 5, 2024
StartEst.
Feb 2024
Primary completionEst.
Dec 2024
CompletionEst.
Feb 2025
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06241391
Lead sponsor
All India Institute of Medical Sciences, Bhubaneswar
Responsible party
Girish Kumar Parida (Assistant Professor, All India Institute of Medical Sciences, Bhubaneswar) — Principal investigator
First posted
Feb 5, 2024
Start date
Feb 2024 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Feb 8, 2024

Study contacts

Dr.Girish Kumar Parida, MD
Contact
grissh135@gmail.com
+91 9968856817

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion